Denali Therapeutics Inc.

DNLI - CIK 0001714899

Market cap$3.23 B

Rank#1749

SEC filings763

Denali Therapeutics Inc. trades as DNLI and has a market capitalization of $3.23 B, making it the #1749 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00 and net income of -$512.54M. This page tracks Denali Therapeutics Inc. through 763 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$0.00FY 2025

Net income (latest FY)-$512.54MFY 2025

Operating cash flow (latest FY)-$412.60MFY 2025

Total assets (latest FY)$1.14BFY 2025

Financial performance

Net profit margin compressed from -28.1% to -43.9% over the same period - every figure below comes from the company's audited annual filings.

DNLI annual revenueView details

Key statistics

Market cap: $3.23 B
Share price (derived)market cap / shares outstanding: $20.36
EPS (diluted)FY 2025: $-2.97
Shares outstandingas of 2026-05-01: 0.16B
Total equityas of 2026-03-31: $926.10M
Return on equity: -55.3%
Cash & equivalentsas of 2026-03-31: $387.63M
Current ratioas of 2026-03-31: 9.28

Latest filings

Filing	Type	Filed
Major company event	8-K	2026-05-22
SCHEDULE 13G	-	2026-05-15
Quarterly report	10-Q	2026-05-07
Major company event	8-K	2026-05-07
SCHEDULE 13G/A	-	2026-05-06
3/A	-	2026-04-21
Proxy materials	DEFA14A	2026-04-21
Annual report to shareholders	ARS	2026-04-21

Browse the full filing history (763 filings)

Recent press releases

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease2026-05-21
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease | Denali Therapeutics
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights2026-05-07
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights | Denali Therapeutics
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)2026-04-03
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) | Denali Therapeutics
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights2026-02-26
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Denali Therapeutics
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™2026-02-05

Similar companies

The largest companies sharing Denali Therapeutics Inc.'s SEC industry classification (biological products, (no diagnostic substances)).

AMGNAmgen Inc.$183.41 B DNLI vs AMGN

GILDGilead Sciences, Inc.$151.05 B DNLI vs GILD

ARGXargenx SE$53.35 B DNLI vs ARGX

RVMDRevolution Medicines, Inc.$30.65 B DNLI vs RVMD

BIIBBiogen Inc.$28.68 B DNLI vs BIIB

Frequently asked questions

What is Denali Therapeutics Inc.'s market cap?

Denali Therapeutics Inc. (DNLI) has a market capitalization of $3.23 B as of 2026-06-10, ranking #1749 among US-listed companies.

How much revenue does Denali Therapeutics Inc. make?

Denali Therapeutics Inc. reported revenue of $0.00 for fiscal year 2025.

Is Denali Therapeutics Inc. profitable?

In its latest fiscal year Denali Therapeutics Inc. reported a net loss of $512.54M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.